Table 2 Muscle mass, physical activity and fatty acid composition in plasma phospholipid in the groups during the intervention.
Group | Baseline | 24 weeks | Δ | |
|---|---|---|---|---|
Muscle mass (kg) | no Ex + placebo | 37.8 ± 1.5 | 37.4 ± 1.5 | − 0.5 ± 0.3 |
Ex + placebo | 36.2 ± 1.4 | 36.3 ± 1.4 | 0.2 ± 0.2 | |
Ex + LCPUFA | 38.3 ± 1.7 | 38.3 ± 1.7 | 0.0 ± 0.1 | |
Step (/day) | no Ex + placebo | 6,716 ± 621 | 6,393 ± 563 | − 322 ± 301 |
Ex + placebo | 5,935 ± 419 | 7,198 ± 383** | 1,264 ± 311## | |
Ex + LCPUFA | 7,807 ± 794 | 8,587 ± 642* | 780 ± 358# | |
FA composition in plasma PL | ||||
PA (%) | no Ex + placebo | 27.1 ± 0.2 | 26.7 ± 0.2* | − 0.4 ± 0.2 |
Ex + placebo | 26.9 ± 0.2 | 26.5 ± 0.2* | − 0.4 ± 0.2 | |
Ex + LCPUFA | 27.0 ± 0.2 | 26.8 ± 0.3 | − 0.3 ± 0.2 | |
SA (%) | no Ex + placebo | 14.4 ± 0.2 | 14.6 ± 0.2 | 0.2 ± 0.2 |
Ex + placebo | 14.7 ± 0.1 | 14.6 ± 0.2 | − 0.1 ± 0.1 | |
Ex + LCPUFA | 14.1 ± 0.3 | 14.4 ± 0.3 | 0.4 ± 0.2 | |
OA (%) | no Ex + placebo | 9.2 ± 0.2 | 9.1 ± 0.2 | − 0.1 ± 0.2 |
Ex + placebo | 9.4 ± 0.2 | 9.0 ± 0.2* | − 0.5 ± 0.2 | |
Ex + LCPUFA | 9.6 ± 0.2 | 8.9 ± 0.1** | − 0.7 ± 0.2 | |
LA (%) | no Ex + placebo | 19.9 ± 0.4 | 19.1 ± 0.5 | − 0.7 ± 0.4 |
Ex + placebo | 19.9 ± 0.6 | 19.7 ± 0.5 | − 0.1 ± 0.5 | |
Ex + LCPUFA | 20.7 ± 0.6 | 18.9 ± 0.5** | − 1.8 ± 0.3 | |
ARA (%) | no Ex + placebo | 10.0 ± 0.3 | 9.8 ± 0.3 | − 0.2 ± 0.2 |
Ex + placebo | 9.5 ± 0.3 | 9.7 ± 0.4 | 0.3 ± 0.3 | |
Ex + LCPUFA | 9.7 ± 0.4 | 10.6 ± 0.3** | 0.9 ± 0.2## | |
EPA (%) | no Ex + placebo | 2.1 ± 0.2 | 2.7 ± 0.4 | 0.6 ± 0.4 |
Ex + placebo | 2.2 ± 0.2 | 2.7 ± 0.3 | 0.5 ± 0.3 | |
Ex + LCPUFA | 2.1 ± 0.3 | 2.4 ± 0.2 | 0.3 ± 0.3 | |
DHA (%) | no Ex + placebo | 7.6 ± 0.3 | 7.4 ± 0.3 | − 0.1 ± 0.2 |
Ex + placebo | 7.6 ± 0.3 | 7.6 ± 0.4 | 0.0 ± 0.2 | |
Ex + LCPUFA | 7.1 ± 0.3 | 8.3 ± 0.2** | 1.3 ± 0.2## | |
EPA/ARA | no Ex + placebo | 0.22 ± 0.02 | 0.28 ± 0.05 | 0.07 ± 0.04 |
Ex + placebo | 0.25 ± 0.03 | 0.30 ± 0.04 | 0.05 ± 0.04 | |
Ex + LCPUFA | 0.23 ± 0.04 | 0.23 ± 0.02 | 0.01 ± 0.03 | |